title: [Essential thrombocytemia and other myeloproliferations with thrombocytemia in the data of the register of patients treated with Thromboreductin till the end of 2006].
abstract: Since 2005, registers of patients treated with Thromboreductin (anagrelid) kept by some centres in the Czech Republic have been supplied with data concerning patients whose treatment with this preparation started in 2004. The purpose of the register is to record responses to therapy by Thromboreductin and adverse events in patients with essential thrombocytemia and other myeloproliferations, and to subsequently analyse the data. Another objective is to detect predisposition to clinical symptomatology and disease complications. Apart from thrombocyte count, additional risk factors are monitored. The database currently contains data for 336 patients. Initial analyses of data from the register point to the fact that anagrelid is a highly effective thromboreductive agent the administration of which is associated with relatively low incidence of adverse events (11.8 %) of mild and usually transitory nature. The therapeutic objective is attained at a relatively slow rate (according to overall stratification under 400 or under 600 x 10(9)/l thrombocytes), which is probably due to insufficient dose adjustment.
authors: Oddelení klinické hematologie FN Brno. m.penka@fnbrno.cz
authors: M
authors: M
authors: Penka
authors: J
authors: J
authors: Schwarz
authors: T
authors: T
authors: Pavlík
authors: R
authors: R
authors: Pytlík
authors: M
authors: M
authors: Doubek
authors: P
authors: P
authors: Dulícek
authors: D
authors: D
authors: Pospísilová
authors: J
authors: J
authors: Kissová
authors: A
authors: A
authors: Hlusí
authors: M
authors: M
authors: Schützová
authors: O
authors: O
authors: Cerná
authors: Y
authors: Y
authors: Brychtová
authors: T
authors: T
authors: Szotkowski
authors: Z
authors: Z
authors: Volková
authors: J
authors: J
authors: Seghetová
authors: V
authors: V
authors: Vozobulová
authors: I
authors: I
authors: Hadacová
authors: I
authors: I
authors: Hochová
authors: J
authors: J
authors: Voglová
authors: T
authors: T
authors: Lhotanová
authors: B
authors: B
authors: Bubeník
authors: O
authors: O
authors: Zapletal
authors: M
authors: M
authors: Vránová
authors: M
authors: M
authors: Micaníková
authors: L
authors: L
authors: Dusek
mesh_terms: D000328:Adult; D005260:Female; D005343:Fibrinolytic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009196:Myeloproliferative Disorders / Q000097:blood / Q000188:drug therapy*; D010975:Platelet Aggregation Inhibitors / Q000009:adverse effects / Q000627:therapeutic use*; D010976:Platelet Count; D011087:Polycythemia Vera / Q000097:blood / Q000188:drug therapy; D011799:Quinazolines / Q000009:adverse effects / Q000627:therapeutic use*; D013922:Thrombocytosis / Q000097:blood / Q000188:drug therapy*
chemical_list: D005343:Fibrinolytic Agents; D010975:Platelet Aggregation Inhibitors; D011799:Quinazolines; C021139:anagrelide